Mouse anti-Human ACE2 Monoclonal Antibody | anti-ACE2 antibody

Recombinant Anti-ACE2 Neutralizing Antibody

Cat. Num. AAA8118898

• Reactivity: Human
• Applications: ELISA, Immunohistochemistry, Flow Cytometry, Functional Assay, Neutralization Assay
• Purity: Protein A
• Synonyms: ACE2; Monoclonal Antibody; Recombinant Anti-ACE2 Neutralizing Antibody; ACE2 Neutralizing Antibody; Mouse Mab; Anti-ACEH Antibody; angiotensin I converting enzyme 2; anti-ACE2 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: Mouse IgG1
• Clone Number: MM36H
• Specificity: Human ACE2
• Purity/Purification: Protein A
• Form/Format: Liquid. 0.2um filtered solution in PBS

• Applicable Applications for anti-ACE2 antibody: ELISA (EIA), Immunohistochemistry-Paraffin (IHC-P), Flow Cytometry (FC/FACS), Neutralization
• Application Notes: ELISA: 0.5-1ug/mL; IHC-P: 1-10ug/mL
• Antibody Type: Recombinant Antibody
• Immunogen: Recombinant Human ACE2 Protein
• Endotoxin: <3EU/mg
• Conjugation: Unconjugated
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human ACE2 (rh ACE2. Met1-Ser740; NP_068576.1). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
• Preparation and Storage: This antibody can be stored at 2-8 degree C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20 degree C to -80 degree C. Preservative-Free. Avoid repeated freeze-thaw cycles.; This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Testing Data

(The neutralization activity is Measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 (2019-nCoV) Spike Pseudovirus under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody. Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. The IC50 is typically 2.375 ug/mL.)

ELISA (EIA)

(Serial dilutions of Anti-ACE2 Neutralizing Antibody was detected by SARS-CoV-2 (2019-nCoV) Inhibitor Screening ELISA Kit. The IC50 is typically 1.20 nM.)

Immunohistochemistry (IHC)

(Immunochemical staining of human ACE2 in human kidney with mouse monoclonal antibody in 5 ug/ml, formalin-fixed paraffin embedded sections.)

Immunohistochemistry (IHC)

(Immunochemical staining of human ACE2 in human testis with mouse monoclonal antibody in 5 ug/ml, formalin-fixed paraffin embedded sections.)

Flow Cytometry (FC/FACS)

(Flow cytometric analysis of Human ACE2 expression on ACE2-transfected 293T cells. Cells were stained with purified anti-Human Human ACE2, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.)

Related Product Information for anti-ACE2 antibody

Background: Angiotensin-converting enzyme 2 (ACE2), a first homolog of ACE, regulates the renin angiotensin system (RAS) by counterbalancing ACE activity. Accumulating evidence in recent years has demonstrated a physiological and pathological role of ACE2 in the cardiovascular, renal and respiratory systems. ACE2 also has an important role in blood pressure control. This enzyme, an homolog of ACE, hydrolyzes angiotensin (Ang) I to produce Ang-(1-9), which is subsequently converted into Ang-(1-7) by a neutral endopeptidase and ACE. ACE2 releases Ang-(1-7) more efficiently than its catalysis of Ang-(1-9) by cleavage of Pro(7)-Phe(8) bound in Ang II. Thus, the major biologically active product of ACE2 is Ang-(1-7), which is considered to be a beneficial peptide of the RAS cascade in the cardiovascular system. A physiological role for ACE2 has been implicated in hypertension, cardiac function, heart function and diabetes, and as a receptor of the severe acute respiratory syndrome coronavirus. In the acute respiratory distress syndrome (ARDS), ACE, AngII, and AT1R promote the disease pathogenesis, whereas ACE2 and the AT2R protect from ARDS. Importantly, ACE2 has been identified as a key SARS-coronavirus receptor and plays a protective role in severe acute respiratory syndrome (SARS) pathogenesis. Furthermore, the recent explosion of research into the ACE2 homolog, collectrin, has revealed a new physiological function of ACE2 as an amino acid transporter, which explains the pathogenic role of gene mutations in Hartnup disorder. This review summarizes and discusses the recently unveiled roles for ACE2 in disease pathogenesis.

References

Koitka A, et al. (2008) Angiotensin converting enzyme 2 in the kidney. Clin Exp Pharmacol Physiol. 35(4): 420-5.Raizada MK, et al. (2007) ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol. 50(2): 112-9.Imai Y, et al. (2007) Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J. 74(3): 405-10.Turner AJ, et al. (2004) ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 25(6): 291-4.